EUCTR2010-024646-30-GBActive, not recruitingPhase 1
Anti-viral prophylaxis for prevention of cytomegalovirus (CMV) reactivation in immunocompetent patients in critical care. - Antiviral Prophylaxis to Prevent Cytomegalovirus Reactivation in IT
niversity Hospitals Birmingham NHS Foundation Trust0 sites124 target enrollmentStarted: January 24, 2011Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 124
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Total hospital stay of less than 7 days •This study aims to assess prophylaxis to prevent CMV reactivation. Patients screened for inclusion will include those hospitalised for less than 7 days prior to admission to intensive care in order to minimise the inclusion of patients admitted late on in their disease process, with pre-existing critical illness CMV reactivation. Inpatients deemed medically fit in the 7 days prior to ICU admission, eg rehab wards will be accepted for study inclusion CMV seropositive •Patients testing CMV positive only will be approached for inclusion in the interventional arm of the study. Patients testing CMV negative will enter the observational arm of the study, and no patient identifiers will be retained. ICU stay of >48 hours •Patient recruitment will be deferred until the end of a 24hr period on the ICU. This period is essential in order to develop a rapport with the patient and family as part of the consent process, to obtain results of CMV status assays, and to make an assessment regarding suitability of the patient for inclusion in the study. Mechanically ventilated, anticipated to continue for > 48 hours •In order to minimise the numbers of patients receiving therapy unnecessarily, and maximise the likelihood of identifying a clinical effect, the study group selects patients with higher risk of reactivation based on previous publications.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 141
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
Exclusion Criteria
- •Age <18 years Pregnancy or breast feeding Expected to survive < 48hrs Confirmed immunosuppression •Known or suspected Human Immunodeficiency Virus infection •Known or suspected underlying immunodeficiency (organ transplant, congenital immunodeficiency, in receipt of immunosuppressive medication e.g. azathioprine, tacrolimus, cyclosporine, sirolimus, cyclophosphamide within 30 days, steroids allowed up to 10mg prednisolone/day on average over 30 days, or stress dose hydrocortisone at up to 400mg/day, short doses of steroids allowed for up to 10 days. •Receipt of chemotherapeutic agent within the last 6 months Severe neutropenia (neutophil count <1000/mm3) Use of systemic antiviral medication within the last 7 days Allergy to study drugs Isolated brain injury
Investigators
Similar Trials
Active, not recruiting
Phase 1
Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study investigating efficacy and safety of Cytotect FH, nanometer filtered (BT094)Congenital CMV infection after primary CMV infection during pregnancyMedDRA version: 18.0Level: LLTClassification code 10010420Term: Congenital CMV infectionSystem Organ Class: 100000004850EUCTR2007-004692-19-DEBiotest AG16,000
Active, not recruiting
Phase 1
Prevention of congenital CMV infection in infants of mothers with primary CMV infection during pregnancyCONGENITAL CMV INFECTION IN NEWBORN FROM MOTHERS WITH PRIMARY CMV INFECTION DURING PREGNANCYMedDRA version: 14.1Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10010420Term: Congenital CMV infectionSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2007-004692-19-ITBIOTEST AG25,000
Active, not recruiting
Phase 1
Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study investigating efficacy and safety of Cytotect FH, nanometer filtered (BT094)Congenital CMV infection after primary CMV infection during pregnancyMedDRA version: 17.0Level: LLTClassification code 10010420Term: Congenital CMV infectionSystem Organ Class: 100000004850EUCTR2007-004692-19-HUBiotest AG15,474
Active, not recruiting
Phase 1
Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study investigating efficacy and safety of Cytotect FH, nanometer filtered (BT094)Congenital CMV infection after primary CMV infection during pregnancyMedDRA version: 19.0Level: LLTClassification code 10010420Term: Congenital CMV infectionSystem Organ Class: 100000004850EUCTR2007-004692-19-ATBiotest AG16,000
Active, not recruiting
Phase 1
Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study investigating efficacy and safety of Cytotect FH, nanometer filtered (BT094)EUCTR2007-004692-19-BEBiotest AG16,000